Sypharma

From a dedicated facility in Dandenong, Victoria, this Australian contract manufacturing and product development partner delivers end-to-end capabilities across therapeutic goods, veterinary products and consumer items. Backed by TGA licensing and a current license MI-24032006-LI-001174-11, it supports projects from early development through commercial-scale manufacturing with a focus on aseptic fill & finish and rigorous quality control.

Core capabilities include:

• Aseptic Fill & Finish with Class A & B clean rooms for aseptic operations and Class C for terminally sterilized products
• Terminal sterilization and non-sterile manufacturing with GMP-grade excipients and formulation support
• IV fluid manufacturing with automated, scalable processes
• In-house quality control laboratory with rapid chemistry and microbiology testing, in-process control and release testing
• Biopharmaceutical formulation and product development, including vaccine development partnerships
• Medical device manufacturing, packaging and bulk supply
• Raw material management, purified water systems and utilities
• End-to-end packaging capabilities and collaborations (including exclusive access to Schott Ready to Use Sterile Glass Vial Kits in AU/NZ)

Strategic collaborations underpin vaccine development and manufacturing initiatives, including the Genetis vaccine hub for mRNA, DNA and recombinant vaccines, plus partnerships with universities and industry groups. Involvement with programs such as the University of Queensland’s rapid-response vaccine pipeline for SARS-CoV-2 fill/finish demonstrates capacity to support clinical trials and accelerated programs.

Located in Dandenong, this partner emphasises speed, regulatory compliance and end-to-end service, enabling clients to translate concepts into validated products while meeting market needs across Australia and New Zealand.